Orforglipron
27 Inquiries
2212020-52-3
china
1kg,25kg
2023-11-19
Rimegepant Sulfate,Fezolinetant,Ubrogepant
-
Product Description
-
Seller Information
-
Inquiry History
-
DescriptionECHEMI Editorial ReferenceOrforglipron is an oral, non-peptide, small-molecule glucagon-like peptide-1 receptor agonist developed by Eli Lilly and Company as a weight-loss drug. Currently, the drug is still in Phase III clinical trials and has not yet received approval from the U.S. Food and Drug Administration (FDA). Eli Lilly's CEO expects the FDA to approve its investigational oral weight-loss drug, orforglipron, by March 2026, and to submit an application for the treatment of type 2 diabetes by the end of 2026.Basic Info
-
Product Name:
Orforglipron
Other Name:1,2,4-Oxadiazol-5(2H)-one, 3-[(1S,2S)-1-[2-[[(4S)-2-(4-fluoro-3,5-dimethylphenyl)-3-[3-(4-fluoro-1-methyl-1H-indazol-5-yl)-2,3-dihydro-2-oxo-1H-imidazol-1-yl]-2,4,6,7-tetrahydro-4-methyl-5H-pyrazolo[4,3-c]pyridin-5-yl]carbonyl]-5-[(4S)-tetrahydro-2,2-dimethyl-2H-pyran-4-yl]-1H-indol-1-yl]-2-methylcy...;LY3502970;GLP-1 receptor agonist 1 USP/EP/BP;Orforglipron;Orforglipron（LY3502970）;LY3502970 (Orforglipron);3-((1S,2S)-1-(5-((S)-2,2-dimethyltetrahydro-2H-pyran-4-yl)-2-((S)-3-(3-(4-fluoro-1-methyl-1H-indazol-5-yl)-2-oxo-2,3-dihydro-1H-imidazol-1-yl)-2-(4-fluoro-3,5-dimethylphenyl)-4-methyl-4,5,6,7-tetrahydro-2H-pyrazolo[4,3-c]pyridine-5-carbonyl)-1H-indol-1-yl)-2-methylcyclopropyl)-1,2,4-oxadiazol-5(4H)-one;OWL 833
CAS No.:2212020-52-3
Molecular Formula:C48H48F2N10O5
InChIKeys:USUWIEBBBWHKNI-BBGRWQLENA-N
Molecular Weight:882.97
EC Number:278-636-5
Color/Form:Off-white to light yellow
Categories:
Characteristics-
Density:
1.50±0.1 g/cm3(Predicted)
PKA:7.33±0.20(Predicted)
Critical Temperature & Pressure:Store at -20°C
-
-
Seller Information
-
Business Type:
Manufactory
-
Main Products:
Rimegepant Sulfate,Fezolinetant,Ubrogepant
-
Location:
Chengdu Tianfu International Bio-town (269 Fenghuang Road, Shuangliu District) Sichuan Province,China
-
Payment Terms:
TT against copy of documents,L/C,TT against B/L draft before shipment,100% TT in advance
-
Average lead Time:
10
-
Total Annual Revenue:
$5 million-$10 million
-
Total Employees:
11-50
-
Year of Establishment:
2014
-
-
Inquiry History27 Inquiries
Country Product Purchase Quantity Date Posted 
Bulgaria
orforglipron
1 KG Aug 27, 2025 
Austria
Orforglipron
1000 MT Jun 12, 2026 
Switzerland
Orforglipron
10 MG Apr 25, 2026 
United States
Orforglipron
20 G Apr 3, 2026
United States
Orforglipron
10 G Mar 29, 2026
United States
oforglipron
3 KG Jul 4, 2025 
India
orforglipron
1.00 G Jul 16, 2026
United States
orforglipron
10 G Apr 20, 2026
United States
Orforglipron
10 G Apr 6, 2026
United States
orforglipron
1 G Mar 24, 2026 
Germany
Orforglipron
2 G Mar 23, 2026 
Bangladesh
Orforglipron
500.00 KG Mar 9, 2026
United States
Orforglipron
10 G Feb 28, 2026 
United Kingdom
Orforglpron
50 G Feb 12, 2026
United States
orforglipron
1 KG Feb 6, 2026 
Lithuania
Orforglipron
6 G Jan 23, 2026 
China
Orforglipron
50 KG Nov 10, 2025
United Kingdom
Orforglipron
1 G Jul 9, 2026 
Belgium
Orforglipron
1 G Jun 14, 2026 
Puerto Rico
Orforglipron
1 G Mar 2, 2026 Post an enquiry for this product